Table 1.

Response 6 months after the end of 48–52 weeks of Peg-IFN-α and after 48–52 weeks of NA treatment.

Treatment	HBeAg Status (BL)	HBeAg/Anti-HBe SC	HBV-DNA <60–80 IU/mL	ALT Normalization	HBsAg Loss	References
Peg-IFN-α 2a 180 ug qw	Positive	32%	14%	41%	3%	[34,35]
Peg-IFN-α 2b 100 ug qw	Positive	29%	7%	32%	7%	[36]
Peg-IFN-α 2a 180 ug qw	Negative	na	19%	59%	4%	[37]
ETV 0.5 mg qd	Positive	21%	67%	68%	2%	[72]
ETV 0.5 mg qd	Negative	na	90%	78%	0%	[73]
TDF 245 mg qd	Positive	21%	76%	68%	3%	[74]
TDF 245 mg qd	Negative	na	93%	76%	0%	[74]
TAF 25 mg qd	Positive	10%	64%	72%	1%	[78]
TAF 25 mg qd	Negative	na	94%	83%	0%	[79]

BL: baseline; SC: sero-conversion; Peg-IFN-α: pegylated interferon; qw: quoad week; qd: quoad die; ETV: entecavir; TDF: tenofovir dipovixil; TAF: tenofovir alafenamide.